Albumin Binding Peptide Conjugates for Lymph Node Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current peptide vaccines for cancer and other diseases face limitations in potency due to poor targeting to lymph nodes, where immune responses are primed, necessitating improved compositions for enhanced antigenicity.
Innovation Solution
Development of albumin binding peptides covalently linked to immunomodulatory molecules, such as peptide antigens or molecular adjuvants, to enhance antigenicity and direct these molecules to the lymphatic system via albumin hitchhiking, utilizing linker domains like Gly-Ser or PEG for improved immune response activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptide vaccines are administered conventionally, then they are simple to manufacture and administer, but they have poor targeting to lymph nodes and limited potency
Solution Approach 1:
The patent creates composite vaccine compositions by conjugating peptide antigens with albumin-binding moieties (such as albumin itself or albumin-binding peptides). This composite structure enables the vaccine to exploit the albumin transport pathway for targeted delivery to lymph nodes, thereby resolving the contradiction between maintaining simplicity and improving potency through enhanced lymph node targeting.
Solution Approach 2:
The patent introduces albumin or albumin-binding peptides as intermediary carriers that mediate the transport of peptide antigens to lymph nodes. This intermediary mechanism allows conventional peptide vaccines to achieve targeted delivery without requiring complex delivery systems, thus improving potency while relatively maintaining simplicity of the overall approach.
2Reliability
If diacyl lipids with PEG spacers are added to peptide antigens to achieve lymph node targeting, then targeting is improved, but the composition becomes more complex
Solution Approach 1:
The patent changes the key parameter of the carrier molecule from diacyl lipids with PEG spacers to albumin or albumin-binding peptides. This parameter change maintains the lymph node targeting function while simplifying the composition, as albumin is a naturally occurring protein that can be more easily integrated into vaccine formulations compared to synthetic lipid-PEG conjugates.
Solution Approach 2:
The patent uses albumin-binding peptides that replicate the lymph node targeting function of albumin without requiring the full albumin structure. These peptide copies or mimics provide the essential targeting capability with reduced molecular complexity, offering a simplified alternative to diacyl lipid-PEG conjugates while maintaining effective lymph node delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The albumin binding peptide conjugates effectively accumulate in lymph nodes, enhancing immune activation and antigenicity, leading to increased immune responses and potential therapeutic benefits in treating cancer or infectious diseases.
Implementation Method 1
The mechanism of action is thought to involve binding of endogenous albumin upon injection, which allows peptide antigens to 'hitchhike' to the draining lymph node
Data Source
AI summary
The present invention provides a conjugate comprising an albumin binding peptide and a cargo, compositions for directing cargos to the lymphatic system, and vaccines. The methods of the invention can be used to increase an immune response, or to treat cancer or an infectious disease.